Reducing sphingolipid synthesis orchestrates global changes to extend yeast lifespan.

Area of Science:

• Gerontology
• Molecular Biology
• Biochemistry

Background:

• Aging and longevity research seeks to improve quality of life and lifespan.
• Rapamycin treatment and calorie restriction are key strategies for enhancing longevity.
• Myriocin, an inhibitor of sphingolipid synthesis, is a newly explored longevity intervention.

Purpose of the Study:

• To investigate the molecular mechanisms by which low-dose myriocin treatment extends yeast lifespan.
• To analyze the global gene expression changes induced by myriocin treatment in yeast.
• To identify conserved signaling pathways modulated by myriocin that impact aging processes.

Main Methods:

• Yeast (Saccharomyces cerevisiae) lifespan assays.
• Genome-wide gene expression profiling (microarrays or RNA-Seq).
• Analysis of conserved signaling pathways including Snf1/AMPK, PKA, and TORC1.

Main Results:

• Myriocin treatment significantly increased yeast lifespan.
• Myriocin altered the expression of approximately 40% of the yeast genome, with 1252 genes up-regulated and 1497 down-regulated.
• Key aging-related pathways, including Snf1/AMPK activation and PKA/TORC1 down-regulation, were modulated by myriocin.

Conclusions:

• Myriocin treatment induces broad cellular changes in yeast, mimicking effects of rapamycin and calorie restriction.
• The observed pathway modulation suggests a conserved mechanism for lifespan extension.
• Myriocin and related compounds hold promise for mitigating age-related diseases and enhancing health span in humans.